Drug intelligence / Profile preview

MAb-10X-01X

Development stage: Preclinical
Lead developer: MedAbome
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

MAb-10X-01X is a preclinical monoclonal antibody candidate being developed by MedAbome for the treatment of sepsis, inflammatory diseases, and autoimmune diseases. The therapeutic is designed to target two undisclosed biological molecules, though the specific molecular targets and mechanism of action have not been publicly revealed by the developer. As of early 2024, the program remains in the preclinical stage of development, aimed at addressing systemic inflammatory responses and autoimmune dysfunction.

Beyond the preview

Go deeper on MAb-10X-01X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAb-10X-01X.

Explore the full profile